Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
Lilly's 2026 TRIUMPH-1 topline Phase 3 release reported 28.3% average reduction at 80 weeks for 12 mg and 30.3% in a selected 104-week extension group
Tissue distribution favors areas with high GLP-1 and GIP receptor expression: pancreas, gut, brain, and adipose tissue
Finally, as less Ozempic is in your system, you will begin to notice an increase in appetite and less fullness after meals
#PharmaNews #GLP1 #ObesityTreatment #EliLilly #NovoNordisk #HealthcareTrends #PharmaIndustry To view or add a comment, sign in A Turning Point in Diabetes & Obesity Care Semaglutide Goes Off-Patent
